A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor

Brief description of study

To evaluate the efficacy of pemigatinib in participants with locally advanced/metastatic or surgically unresectable solid tumor malignancy with an activating FGFR mutation or translocation.

Clinical Study Identifier: s19-01025
ClinicalTrials.gov Identifier: NCT03822117

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.